Patents Assigned to The United States of America, as represented by the Secretary, Department of Health and Human
  • Patent number: 12270881
    Abstract: Kinetic monitoring of in vivo metabolism of labelled tracers is based on singular value decomposition or Tucker Decomposition of magnetic resonance spectral image data. Data decomposition is used in conjunction with rank reduction to improve signal-to-noise ratio. Rank reduction can be applied in one or more of a spectral, spatial, or temporal dimension. Rank is generally reduced based on a number of expected analytes/metabolites or fit of measured data to a model.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: April 8, 2025
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Jeffrey R. Brender, James B. Mitchell, Kazutoshi Yamamoto, Shun Kishimoto, Jeeva P. Munasinghe, Hellmut Merkle, Murali K. Cherukuri
  • Patent number: 12270814
    Abstract: Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.
    Type: Grant
    Filed: October 6, 2023
    Date of Patent: April 8, 2025
    Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human Services
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Patent number: 12269155
    Abstract: The present disclosure provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a coronavirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a coronavirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present disclosure provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one coronavirus immunogenic glycoprotein fragment, as well as pharmaceutical compositions comprising the vaccine vectors.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: April 8, 2025
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Thomas Jefferson University, University of Maryland, Baltimore
    Inventors: Reed F. Johnson, Matthias Schnell, Lisa E. Hensley, Christoph Wirblich, Christopher M. Coleman, Matthew S. Frieman
  • Patent number: 12270738
    Abstract: Disclosed herein are compositions for fixing tissue for cytologic, histomorphologic, and/or molecular analysis (e.g., DNA, RNA, and/or protein analysis). In some embodiments, the fixatives are aldehyde-free fixatives, for example, formaldehyde- or formalin-free fixatives. Particular disclosed compositions include buffered ethanol. The buffer is a phosphate buffer or phosphate buffered saline (PBS) in some examples. In further embodiments, the fixative includes additional components, such as glycerol and/or acetic acid.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: April 8, 2025
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen M. Hewitt, Joon-Yong Chung, Candice D. Perry, Robert A. Star
  • Patent number: 12268700
    Abstract: Disclosed is a compound of the formula (I) or (II): wherein a f are as described herein. The compounds are useful in the activation of Type II NKT cells and in treating cancer.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: April 8, 2025
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Connecticut
    Inventors: Lise H. Pasquet, Jay A. Berzofsky, Amy R. Howell, Masaki Terabe, Kaddy Camara, Stewart K. Richardson
  • Patent number: 12268737
    Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
    Type: Grant
    Filed: April 26, 2024
    Date of Patent: April 8, 2025
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Secretary, Department of Health and Human Services
    Inventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
  • Patent number: 12269872
    Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: April 8, 2025
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Robert Seder, Lawrence Wang, Rachel Vistein, Joseph Francica
  • Publication number: 20250109175
    Abstract: Embodiments of recombinant HIV-1 gp120 proteins that contain a V1 deletion are disclosed. Also provided are gp140, gp145, and gp160 proteins containing the V1 deletion, as well as HIV-1 Env ectodomain trimers containing protomers containing the V1 deletion. Nucleic acid molecules encoding these proteins are also provided. In several embodiments, the disclosed recombinant HIV-1 proteins and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
    Type: Application
    Filed: December 5, 2024
    Publication date: April 3, 2025
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, New York University
    Inventors: Genoveffa Franchini, Timothy Cardozo, Manuel Becerra-Flores, Isabela Silva de Castro, Giacomo Gorini, Massimiliano Bissa
  • Publication number: 20250090658
    Abstract: The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.
    Type: Application
    Filed: December 5, 2024
    Publication date: March 20, 2025
    Applicants: Oxford University Innovation Limited, The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Kerry Fisher, Richard Laga, Geoffrey Lynn, Leonard Seymour, Robert Seder
  • Publication number: 20250095390
    Abstract: A method is provided for non-invasively predicting characteristics of one or more cells and cell derivatives. The method includes training a machine learning model using at least one of a plurality of training cell images representing a plurality of cells and data identifying characteristics for the plurality of cells. The method further includes receiving at least one test cell image representing at least one test cell being evaluated, the at least one test cell image being acquired noninvasively and based on absorbance as an absolute measure of light, and providing the at least one test cell image to the trained machine learning model. Using machine learning based on the trained machine learning model, characteristics of the at least one test cell are predicted. The method further includes generating, by the trained machine learning model, release criteria for clinical preparations of cells based on the predicted characteristics of the at least one test cell.
    Type: Application
    Filed: May 13, 2024
    Publication date: March 20, 2025
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Kapil Bharti, Nathan A. Hotaling, Nicholas J. Schaub, Carl G. Simon
  • Patent number: 12251432
    Abstract: Disclosed herein are immunogenic compositions for preventing or treating infection with filarial parasites and biomarkers for diagnosing infection with filarial parasites.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: March 18, 2025
    Assignees: New York Blood Center, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Sara Lustigman, Thomas B. Nutman, Sasisekhar Bennuru
  • Patent number: 12247250
    Abstract: The present invention relates to the rapid and electricity-free, point-of-care, multiplexed detection and quantification of at least one or more nucleic acid sequences from nucleic acids corresponding to a plurality of pathogens or biomarkers using a micropatterned lateral flow device. Rapid and molecular-level sensitive differential diagnosis of a disease condition may be enabled without the need for a delayed laboratory test so that timely treatment can be administered.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: March 11, 2025
    Assignees: GODX, INC, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES
    Inventors: Chang Hee Kim, Wendy A. Henderson, Sarah K. Abey, Nicolaas H. Fourie, Eric G. Ferguson
  • Patent number: 12239654
    Abstract: The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: March 4, 2025
    Assignees: Astrocyte Pharmaceuticals, Inc., Board of Regents, The University of Texas System, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: William S. Korinek, James D. Lechleiter, Theodore E. Liston, Kenneth A. Jacobson
  • Publication number: 20250066452
    Abstract: Therapeutic agents, compositions, and methods are described for use in the treatment of acute or chronic pain, neuroinflammation, or conditions characterized by acute or chronic pain or neuroinflanmmation. The therapeutic agents comprise a synthetic amphipathic helical peptide capable of acting as a mimetic of apoA-I protein.
    Type: Application
    Filed: March 2, 2023
    Publication date: February 27, 2025
    Applicants: UNIVERSITY OF MARYLAND, BALTIMORE, The United States of America, As Represented by The Secretary, Department of Health and Human Servi
    Inventors: Konstantin BIRUKOV, Thomas L. EGGERMAN, Alexander V. BOCHAROV, Cynthia L. RENN
  • Patent number: 12233124
    Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.
    Type: Grant
    Filed: September 6, 2023
    Date of Patent: February 25, 2025
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine
    Inventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
  • Patent number: 12233051
    Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.
    Type: Grant
    Filed: July 14, 2023
    Date of Patent: February 25, 2025
    Assignees: VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Matthew Hall, Daniel J. Urban, John Knight, Ross Holmes, Kyle David Wood, Alex Waterson, Victor M. Darley-Usmar, Leonard M. Neckers
  • Publication number: 20250057949
    Abstract: Disclosed are methods of treating or preventing cancer in a mammal, the method comprising: (a) isolating T cells from a tumor sample from the mammal, wherein the isolated T cells are one or both of exhausted and differentiated, and the isolated T cells have antigenic specificity for a tumor-specific antigen expressed by the tumor sample from the mammal, wherein the tumor-specific antigen is a tumor-specific neoantigen or an antigen with a tumor-specific driver mutation; and optionally expanding the numbers of isolated, tumor antigen-specific T cells; and (b) administering to the mammal (i) the isolated T cells of (a) and (ii) a vaccine which specifically stimulates an immune response against the tumor-specific antigen for which the isolated T cells have antigenic specificity.
    Type: Application
    Filed: December 29, 2022
    Publication date: February 20, 2025
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Sri Krishna, Zhiya Yu, Ken-ichi Hanada, Steven A. Rosenberg
  • Publication number: 20250059508
    Abstract: Disclosed are methods of isolating T cells having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation, the method comprising: identifying one or more genes in the nucleic acid of a cancer cell of a patient, each gene containing a cancer-specific mutation that encodes a mutated amino acid sequence; inducing autologous APCs of the patient to present the mutated amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of preparing a population of cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Application
    Filed: November 6, 2024
    Publication date: February 20, 2025
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv.
    Inventors: Eric Tran, Yong-Chen Lu, Paul F. Robbins, Steven A. Rosenberg
  • Patent number: 12227554
    Abstract: Disclosed are methods of selectively expanding a number of T cells. The methods may comprise: modifying human T cells to express a TCR, wherein the TCR comprises a murine constant region; producing a population of cells comprising a number of human T cells expressing the TCR and a number of human T cells not expressing the TCR; and culturing the population of cells in the presence of (i) irradiated feeder cells, (ii) one or more cytokines, and (iii) an antibody, or an antigen-binding portion thereof, wherein the antibody has antigenic specificity for the murine constant region of the TCR, so as to selectively expand the number of T cells expressing the TCR over the number of T cells not expressing the TCR. Also disclosed are related populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: February 18, 2025
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Drew C. Deniger, Steven A. Feldman, Steven A. Rosenberg
  • Patent number: 12228582
    Abstract: A method and treatment for testing efficiency and effectiveness of a near infrared photoimmunotherapy treatment includes injecting an antibody photosensitizer conjugate (APC) into a patient, applying radiation to the patient, thereby causing the APC to release a ligand, which is excreted in the patient's urine, detecting the presence of the ligand with liquid chromatography-mass spectrometry, measuring and quantifying an amount of the ligand present in the patient's urine based on analytical results of the liquid chromatography-mass spectrometry, and determining the effectiveness of the near infrared photo-immunotherapy treatment based on the measured quantified amount of the ligand present in the patient's urine so as to determine an amount of APC remaining in the patient.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: February 18, 2025
    Assignees: SHIMADZU CORPORATION, The United States of America as Represented By The Secretary of the Department of Health and Human
    Inventors: Hisataka Kobayashi, Masayuki Nishimura